Preferences help
enabled [disable] Abstract
Number of results
2014 | 10 | 1 |
Article title

Cost comparison of treating chronic hepatitis C genotype one with pegylated interferons in Ukraine

Title variants
Languages of publication
Based on the pivotal trial showing no clinicallyrelevant
differences between pegylated interferon α-2b
(Peg-α-2b) and α-2a (Peg-α-2a) combined with ribavirin
for treatment of chronic hepatitis C virus (HCV) genotype
1 infection in Ukraine, a cost-minimization analysis was
performed using a 1 year time horizon and both a health
care and patients’ perspective. A decision tree reflects
treatment pathways. Drug costs were based on drug labeling
and adjusted to the average body mass in Ukraine.
Subgroup analysis was applied to deal with heterogeneity
of patient’s weight causing dose changes. A break-even
price of Peg-α-2a and Peg-α-2b (based on the average dose)
was calculated. Univariate sensitivity analyses and probabilistic
sensitivity analysis were carried out to reflect
decision uncertainty. For an average body weight, total
medical costs per patient differ from US$9220 for Peg-α-2b
to US$9513 for Peg-α-2a from a health care perspective, and
from US$15,212 to US$15,696 from a patients’ perspective. Sensitivity analyses show these results are robust. With
average body weight, the break-even price of Peg-α-2b may
be 7.3% higher than Peg-α-2a to have similar total costs.
Physical description
1 - 1 - 2015
28 - 4 - 2013
8 - 1 - 2014
8 - 10 - 2014
  • [1] Lawn SD, Wilkinson RJ, Lipman MCI, Wood R. Immune reconstitution and “unmasking” of tuberculosis during antiretroviral therapy. Am. J. Respir. Crit. Care Med. 2008 Apr 1;177(7):680-685[WoS]
  • [2] Cheng VCC, Ho PL, Lee RA, Chan KS, Chan KK, Woo PCY, et al. Clinical spectrum of paradoxical deterioration during antituberculosis therapy in non-HIV-infected patients. Eur. J. Clin. Microbiol. Infect. Dis. 2002 Nov;21(11):803-809[Crossref]
  • [3] Melboucy-Belkhir S, Flexor G, Stirnemann J, Morin A-S, Boukari L, Polliand C, et al. Prolonged paradoxical response to anti-tuberculous treatment after infliximab. Int. J. Infect. Dis. 2010 Sep;14 Suppl 3:e333-334[Crossref]
  • [4] Yoon YK, Kim JY, Sohn JW, Kim MJ, Koo JS, Choi JH, et al. Paradoxical response during antituberculous therapy in a patient discontinuing infliximab: a case report. J Med Case Reports. 2009;3:6673
  • [5] Garcia Vidal C, Rodríguez Fernández S, Martínez Lacasa J, Salavert M, Vidal R, Rodríguez Carballeira M, et al. Paradoxical response to antituberculous therapy in infliximab-treated patients with disseminated tuberculosis. Clin. Infect. Dis. 2005 Mar 1;40(5):756-759
  • [6] Hess S, Hospach T, Nossal R, et al. Life- threatening disseminated tuberculosis as a complication of TNF- a blockade in an adolescent. Eur J Pediatr. Volume 170, Number 10, 1337-1342
  • [7] Wallis RS (2008) Tumour necrosis factor antagonists: structure, function, and tuberculosis risks. Lancet Infect Dis 8: 601-611[Crossref][WoS]
  • [8] Brassard P, Kezouh A, Suissa S (2006) Antirheumatic drugs and the risk of tuberculosis. Clin Infect Dis 43: 717-722[WoS][Crossref]
  • [9] Wallis RS (2009) Infectious complications of tumor necrosis factor blockade. Curr Opin Infect Dis 22: 403-409[Crossref][WoS]
  • [10] Wallis RS, Broder MS, Wong JY et al (2004) Granulomatous infectious diseases associated with TNF antagonists. Clin Infect Dis 38: 1261-1265[Crossref]
  • [11] Wallis RS, Broder MS, Wong JY et al (2004) Granulomatous infections due to tumor necrosis factor blockade: correction. Clin Infect Dis 39: 1254-1256[Crossref]
  • [12] Meintjes G, Wilkinson RJ, Morroni C et al (2010) Randomized placebo- controlled trial of prednisone for paradoxical tuberculosis- associated immune reconstitution inflammatory syndrome. AIDS 24: 2381-2390[WoS]
  • [13] Wallis RS, Van Vuuren C, Potgieter S. Adalimumab treatment of life- threatening tuberculosis. Clin. Infect. Dis. 2009 May 15; 48 (10): 1429-1432
  • [14] Blackmore TK, Manning L, Taylor WJ, et al. Therapeutic use of infliximab in tuberculosis to control severe paradoxical reaction of the brain and lymph nodes. Clin. Infect. Dis. 2008 Nov 15; 47 (10): e 83-85
  • [15] Jurisic V, Stojacic- Djenic S, Colovic N and Konjevic G. The role of cytokine in regulation of the natural killer cell activity. Srp Arh Celok Lek. 2008 Jul-Aug;136(7-8):423-429
Document Type
Publication order reference
YADDA identifier
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.